title: Effect of short term and chronic administration of Sutherlandia frutescens on pharmacokinetics of nevirapine in rats.
abstract: Sutherlandia frutescens (sutherlandia), an African herbal supplement was recommended by the South African Ministry of Health for the treatment of AIDS patients. However, no reports yet exist delineating the effect of sutherlandia on pharmacokinetics of antiretroviral agents. Therefore, this investigation aimed at screening the effects of short term and chronic exposure of sutherlandia on oral bioavailability and pharmacokinetics of nevirapine (NVP), a non-nucleoside reverse transcriptase inhibitor, in Sprague Dawley rats. NVP (6 mg/kg) was administered orally alone (control) and with co-administration of sutherlandia; short term (12 mg/kg single dose) and long term (12 mg/kg, once a day for 5 days). No significant difference in the pharmacokinetic parameters of NVP was found upon short-term co-administration of Sutherlandia. However, there was a 50% decrease (p<0.05) in the AUC and C(max) values of NVP after 5 days of chronic exposure with Sutherlandia. In addition, quantitative RT-PCR studies demonstrated a 2-3-fold increase in the hepatic and intestinal mRNA expression of CYP3A2, relative to vehicle control. To further confirm, if this could translate into a clinically relevant pharmacokinetic interaction in patients, we tested this hypothesis employing LS-180 cells as an in vitro induction model for human CYP3A4. Ninety-six hours post treatment, similar to positive control rifampicin (25 μM), sutherlandia extract (300 μg/mL) resulted in elevated m-RNA expression levels and functional activity of CYP3A4 (human homologue of rodent CYP3A2) in LS-180 cells. Taken together, these results suggest that a potential drug-herb interaction is possible when NVP is co-administered with S. frutescens, although this hypothesis still remains to be investigated in a clinical setting.
authors.affiliation: Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108-2718, USA.
authors.forename: Mukul
authors.initials: M
authors.lastname: Minocha
authors.forename: Nanda K
authors.initials: NK
authors.lastname: Mandava
authors.forename: Deep
authors.initials: D
authors.lastname: Kwatra
authors.forename: Dhananjay
authors.initials: D
authors.lastname: Pal
authors.forename: William R
authors.initials: WR
authors.lastname: Folk
authors.forename: Ravinder
authors.initials: R
authors.lastname: Earla
authors.forename: Ashim K
authors.initials: AK
authors.lastname: Mitra
mesh_terms: D000284:Administration, Oral; D000818:Animals; D045744:Cell Line, Tumor; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D065692:Cytochrome P-450 CYP3A Inhibitors; D004353:Drug Evaluation, Preclinical; D007887:Fabaceae; D005562:Formazans; D041743:Herb-Drug Interactions; D006801:Humans; D008297:Male; D019829:Nevirapine / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics* / Q000494:pharmacology; D010936:Plant Extracts / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics* / Q000494:pharmacology; D013778:Tetrazolium Salts; D013997:Time Factors
chemical_list: D065692:Cytochrome P-450 CYP3A Inhibitors; D005562:Formazans; D010936:Plant Extracts; D018894:Reverse Transcriptase Inhibitors; D013778:Tetrazolium Salts; C079782:MTT formazan; D019829:Nevirapine; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human